Pharvaris announced positive top-line data from the CHAPTER-1 Phase 2 clinical study meeting its primary endpoint, with deucrictibant demonstrating statistically significant and clinically meaningful results of deucrictibant as an oral preventative treatment for people living with HAE. Pharvaris plans to present data from the study at future medical meetings. Primary endpoint met; 40 mg/day orally administered deucrictibant significantly reduced mean monthly attack rate by 84.5% compared to placebo. 92.3% reduction in occurrence of moderate and severe attacks 92.6% fewer attacks treated with on-demand medication by participants. Deucrictibant well-tolerated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PHVS:
- Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks
- Pharvaris to Present at the GA²LEN UCARE Conference 2023
- Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer
- Pharvaris names Stefan Abele, Ph.D., as Chief Technical Operations Officer
- Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting